Hydrocortisone

Generic Name: Hydrocortisone
Brand Name: IPOCORT®
Dosage Form: Injection 100mg/2ml
Pharmacological Category: Anti-inflammatory Agents
Therapeutic Category: Corticosteroids
Pregnancy Category: Category C

Pharmacology

Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9.

Pharmacokinetics:

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

Indications:

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Contraindications:

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

Drug Interactions:

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

Side Effects:

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

Storage:

• Store below 30 C°
• Protect from light and freezing

Packing:

• Injection 100mg/2ml: Box of 10 ampoules

stdClass Object ( [nid] => 240 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373659573 [changed] => 1392756930 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 125 [translate] => 0 [vid] => 240 [revision_uid] => 1 [title] => Hydrocortisone [body] =>
Image: 
Brand Name: 

IPOCORT®

Dosage Form: 

Injection 100mg/2ml

Pharmacological Category: 

Anti-inflammatory Agents

Therapeutic Category: 

Corticosteroids

Pregnancy Category: 

Category C

Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9.

Pharmacokinetics: 

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

Indications: 

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Contraindications: 

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

Drug Interactions: 

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

Side Effects: 

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Injection 100mg/2ml: Box of 10 ampoules

[log] => [revision_timestamp] => 1392756930 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-aTcSqa5gxC3qlJ6qWYJHsxgkPEq9KwPBBC-KEX1q3PQ";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/hydrocortisone [field_one_image] => Array ( [0] => Array ( [fid] => 797 [uid] => 1 [filename] => hydrocortisone_s.jpg [filepath] => sites/default/files/images/hydrocortisone_s.jpg [filemime] => image/jpeg [filesize] => 13874 [status] => 1 [timestamp] => 1373610733 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 240 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => IPOCORT® [format] => 1 [safe] =>

IPOCORT®

[view] =>

IPOCORT®

) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid. • Systemic fungal infections unless needed to control drug reactions due to amphotericin B. • Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid. • Systemic fungal infections unless needed to control drug reactions due to amphotericin B. • Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids. • IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]). • Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants. • uppressive doses of corticosteroids. • IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]). • Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants. [format] => 1 [safe] =>

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

[view] =>

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 100mg/2ml [format] => 1 [safe] =>

Injection 100mg/2ml

[view] =>

Injection 100mg/2ml

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance). Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance). Drug Interaction Comments Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen Ketoconazole Possible decrease in metabolic clearance of hydrocortisone Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects NSAIAs Increases the risk of GI ulceration Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution Observe patients receiving both drugs closely for adverse effects of either drug May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued Use aspirin and corticosteroids with caution in hypoprothrombinemia Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines May potentiate replication of some organisms contained in live, attenuated vaccines Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease) [format] => 1 [safe] =>

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

[view] =>

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

) ) [field_indications] => Array ( [0] => Array ( [value] => Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. [format] => 1 [safe] =>

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

[view] =>

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

) ) [field_packing] => Array ( [0] => Array ( [value] => • Injection 100mg/2ml: Box of 10 ampoules [format] => 1 [safe] =>

• Injection 100mg/2ml: Box of 10 ampoules

[view] =>

• Injection 100mg/2ml: Box of 10 ampoules

) ) [field_pdf] => Array ( [0] => Array ( [fid] => 212 [uid] => 1 [filename] => hydrocortisone.pdf [filepath] => sites/default/files/pdf/hydrocortisone.pdf [filemime] => application/pdf [filesize] => 848642 [status] => 1 [timestamp] => 1329494673 [list] => 1 [data] => [i18nsync] => 1 [nid] => 240 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.


Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.


Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.


Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[format] => 1 [safe] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[view] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Anti-inflammatory Agents [format] => 1 [safe] =>

Anti-inflammatory Agents

[view] =>

Anti-inflammatory Agents

) ) [field_precautions] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => Category C [format] => 1 [safe] =>

Category C

[view] =>

Category C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis. [format] => 1 [safe] =>

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

[view] =>

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[view] =>

• Store below 30 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Corticosteroids [format] => 1 [safe] =>

Corticosteroids

[view] =>

Corticosteroids

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [8] => stdClass Object ( [tid] => 8 [vid] => 1 [name] => Corticosteroids [description] => [weight] => 6 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => 1 [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 797 [uid] => 1 [filename] => hydrocortisone_s.jpg [filepath] => sites/default/files/images/hydrocortisone_s.jpg [filemime] => image/jpeg [filesize] => 13874 [status] => 1 [timestamp] => 1373610733 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 240 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
[#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => IPOCORT® [format] => 1 [safe] =>

IPOCORT®

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

IPOCORT®

) [#title] => [#description] => [#children] =>

IPOCORT®

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

IPOCORT®

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Brand Name: 

IPOCORT®

[#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Injection 100mg/2ml [format] => 1 [safe] =>

Injection 100mg/2ml

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Injection 100mg/2ml

) [#title] => [#description] => [#children] =>

Injection 100mg/2ml

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Injection 100mg/2ml

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Dosage Form: 

Injection 100mg/2ml

[#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Anti-inflammatory Agents [format] => 1 [safe] =>

Anti-inflammatory Agents

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Anti-inflammatory Agents

) [#title] => [#description] => [#children] =>

Anti-inflammatory Agents

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Anti-inflammatory Agents

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacological Category: 

Anti-inflammatory Agents

[#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Corticosteroids [format] => 1 [safe] =>

Corticosteroids

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Corticosteroids

) [#title] => [#description] => [#children] =>

Corticosteroids

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Corticosteroids

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Therapeutic Category: 

Corticosteroids

[#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Category C [format] => 1 [safe] =>

Category C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Category C

) [#title] => [#description] => [#children] =>

Category C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Category C

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pregnancy Category: 

Category C

[#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9.

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.


Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.


Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.


Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[format] => 1 [safe] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

) [#title] => [#description] => [#children] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacokinetics: 

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

[#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. [format] => 1 [safe] =>

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

) [#title] => [#description] => [#children] =>

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Indications: 

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

[#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid. • Systemic fungal infections unless needed to control drug reactions due to amphotericin B. • Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid. • Systemic fungal infections unless needed to control drug reactions due to amphotericin B. • Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids. • IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]). • Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants. • uppressive doses of corticosteroids. • IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]). • Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants. [format] => 1 [safe] =>

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

) [#title] => [#description] => [#children] =>

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Contraindications: 

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

[#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance). Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance). Drug Interaction Comments Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen Ketoconazole Possible decrease in metabolic clearance of hydrocortisone Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects NSAIAs Increases the risk of GI ulceration Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution Observe patients receiving both drugs closely for adverse effects of either drug May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued Use aspirin and corticosteroids with caution in hypoprothrombinemia Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines May potentiate replication of some organisms contained in live, attenuated vaccines Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease) [format] => 1 [safe] =>

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

) [#title] => [#description] => [#children] =>

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Drug Interactions: 

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

[#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis. [format] => 1 [safe] =>

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

) [#title] => [#description] => [#children] =>

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Side Effects: 

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

[#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Storage: 

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Injection 100mg/2ml: Box of 10 ampoules [format] => 1 [safe] =>

• Injection 100mg/2ml: Box of 10 ampoules

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Injection 100mg/2ml: Box of 10 ampoules

) [#title] => [#description] => [#children] =>

• Injection 100mg/2ml: Box of 10 ampoules

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Injection 100mg/2ml: Box of 10 ampoules

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Packing: 

• Injection 100mg/2ml: Box of 10 ampoules

[#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [fid] => 212 [uid] => 1 [filename] => hydrocortisone.pdf [filepath] => sites/default/files/pdf/hydrocortisone.pdf [filemime] => application/pdf [filesize] => 848642 [status] => 1 [timestamp] => 1329494673 [list] => 1 [data] => [i18nsync] => 1 [nid] => 240 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
Brand Name: 

IPOCORT®

Dosage Form: 

Injection 100mg/2ml

Pharmacological Category: 

Anti-inflammatory Agents

Therapeutic Category: 

Corticosteroids

Pregnancy Category: 

Category C

Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9.

Pharmacokinetics: 

Readily absorbed after oral administration.Following IM administration, absorption of the water-soluble sodium phosphate and sodium succinate salts is rapid; the rate of absorption of the lipid-soluble acetate is much slower.
The duration of anti-inflammatory activity of hydrocortisone approximately equals the duration of HPA-axis suppression.
Most glucocorticoids are removed rapidly from the blood and distributed to muscle, liver, skin, intestines, and kidneys. Glucocorticoids appear in breast milk and cross the placenta.

Extensively bound to corticosteroid-binding globulin (transcortin) and albumin.
Patients with low serum albumin concentrations may be more susceptible to effects of glucocorticoids than those with normal serum albumin concentrations.

Metabolized in most tissues, but primarily in the liver, to inactive compounds.
Inactive metabolites are excreted by the kidneys, primarily as glucuronides and sulfates, but also as unconjugated products. Small amounts of unmetabolized drugs are also excreted in urine.

Half-life
Following oral or IV administration of hydrocortisone, 1.5–3.5 hours.

Indications: 

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis
with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Contraindications: 

• Known hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosKnown hypersensitivity to hydrocortisone, any ingredient in the respective formulation, or any other corticosteroid.
• Systemic fungal infections unless needed to control drug reactions due to amphotericin B.
• Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.
• uppressive doses of corticosteroids.
• IM administration for conditions prone to bleeding (e.g., idiopathic thrombocytopenic purpura [ITP]).
• Hydrocortisone sodium succinate injection preparations containing benzyl alcohol in premature infants.

Drug Interactions: 

Inhibitors of CYP3A4: potential pharmacokinetic interaction (decreased hydrocortisone clearance).
Inducers of CYP3A4: potential pharmacokinetic interaction (increased hydrocortisone clearance).
Drug Interaction Comments
Amphotericin B Cases of cardiac enlargement and CHF reported with use of hydrocortisone to control adverse reactions to amphotericin B
Anticoagulants, oral Conflicting reports of alterations in the anticoagulant response Monitor prothrombin time frequently
Antidiabetic therapy Increased blood glucose concentrations in diabetes mellitus May require dosage adjustment of concurrent insulin and/or oral hypoglycemic agents
Barbiturates Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Diuretics, potassium-depleting Enhance the potassium-wasting effects of glucocorticoids Monitor for development of hypokalemia
Ephedrine Possible increase in metabolic clearance of hydrocortisone Increased hydrocortisone dosage may be necessary
Estrogens Estrogens may potentiate effects of hydrocortisone Dosage adjustment of hydrocortisone may be required if estrogens are added to or withdrawn from a stable dosage regimen
Ketoconazole Possible decrease in metabolic clearance of hydrocortisone
Inhibits adrenal corticosteroid synthesis, causing adrenal insufficiency during corticosteroid withdrawal May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
Macrolide antibiotics Possible decrease in metabolic clearance of hydrocortisone May need a reduction in dosage of hydrocortisone to avoid potential adverse effects
NSAIAs Increases the risk of GI ulceration
Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Use concurrently with caution
Observe patients receiving both drugs closely for adverse effects of either drug
May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinued
Use aspirin and corticosteroids with caution in hypoprothrombinemia
Phenytoin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Rifampin Possible increase in metabolic clearance of hydrocortisone Increased dosage of hydrocortisone may be necessary
Vaccines and toxoids May cause a diminished response to toxoids and live or inactivated vaccines
May potentiate replication of some organisms contained in live, attenuated vaccines
Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) Live virus vaccines contraindicated in individuals receiving immunosuppressive hydrocortisone doses
Defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued
May need serologic testing to ensure adequate antibody response for immunization; additional doses of the vaccine or toxoid may be necessary
May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)

Side Effects: 

Associated with long-term therapy: bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, oral candidiasis.

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Injection 100mg/2ml: Box of 10 ampoules

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/125 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => هیدروکورتیزون سدیم فسفات [class] => translation-link ) ) ) )
button

CONTACT US:

Head Office:
Address: No.1, Beastoon Ave., Dr. Fatemi Sq., Tehran1431663135 Iran
Tel: (+98 21)-889 65323
Fax: (+98 21)-889 57056
Factory:
Address: Caspian tamin Pharmaceutical Co., Entrance 1, Rasht Industrial Zone, Rasht, Guilan, Iran
Tel: (+98 131) 338-2511- 8
Fax: (+98 131) 338 – 2517